Cannabidiol and its Potential Evidence-Based Psychiatric Benefits – A Critical Review
- 24 January 2024
- journal article
- research article
- Published by Georg Thieme Verlag KG in Pharmacopsychiatry
- Vol. 57 (03) , 115-132
Abstract
The endocannabinoid system shows promise as a novel target for treating psychiatric conditions. Cannabidiol (CBD), a naturally occurring cannabinoid, has been investigated in several psychiatric conditions, with diverse effects and an excellent safety profile compared to standard treatments. Even though the body of evidence from randomised clinical trials is growing, it remains relatively limited in most indications. This review comprises a comprehensive literature search to identify clinical studies on the effects of CBD in psychiatric conditions. The literature search included case studies, case reports, observational studies, and RCTs published in English before July 27, 2023, excluding studies involving nabiximols or cannabis extracts containing CBD and ∆9-tetrahydrocannabinol. Completed studies were considered, and all authors independently assessed relevant publications. Of the 150 articles identified, 54 publications were included, covering the effects of CBD on healthy subjects and various psychiatric conditions, such as schizophrenia, substance use disorders (SUDs), anxiety, post-traumatic stress disorder (PTSD), and autism spectrum disorders. No clinical studies have been published for other potential indications, such as alcohol use disorder, borderline personality disorder, depression, dementia, and attention-deficit/hyperactivity disorder. This critical review highlights that CBD can potentially ameliorate certain psychiatric conditions, including schizophrenia, SUDs, and PTSD. However, more controlled studies and clinical trials, particularly investigating the mid- to long-term use of CBD, are required to conclusively establish its efficacy and safety in treating these conditions. The complex effects of CBD on neural activity patterns, likely by impacting the endocannabinoid system, warrant further research to reveal its therapeutic potential in psychiatry. † Co-senior authorship: Cathrin Rohleder, F. Markus Leweke Received: 25 August 2023 Received: 22 November 2023 Accepted: 04 December 2023 Article published online: 24 January 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, GermanyKeywords
This publication has 114 references indexed in Scilit:
- Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: a positron emission tomography studyMolecular Psychiatry, 2013
- Plasma Concentrations of Endocannabinoids and Related Primary Fatty Acid Amides in Patients with Post-Traumatic Stress DisorderPLOS ONE, 2013
- Cannabidiol for the treatment of cannabis withdrawal syndrome: a case reportJournal of Clinical Pharmacy and Therapeutics, 2012
- Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophreniaTranslational Psychiatry, 2012
- Cannabidiol, a non‐psychotropic component of cannabis, attenuates vomiting and nausea‐like behaviour via indirect agonism of 5‐HT1A somatodendritic autoreceptors in the dorsal raphe nucleusBritish Journal of Pharmacology, 2011
- Modulation of Auditory and Visual Processing by Delta-9-Tetrahydrocannabinol and Cannabidiol: an fMRI StudyNeuropsychopharmacology, 2011
- Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naïve Social Phobia PatientsNeuropsychopharmacology, 2011
- Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary reportJournal of Psychopharmacology, 2010
- Opposite Effects of Δ-9-Tetrahydrocannabinol and Cannabidiol on Human Brain Function and PsychopathologyNeuropsychopharmacology, 2009
- Cannabinoids go nuclear: evidence for activation of peroxisome proliferator‐activated receptorsBritish Journal of Pharmacology, 2007